Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biotech firm Morphotek has entered into a collaboration with the John Wayne Cancer Institute for the discovery and development of therapeutic antibodies to a cancer-associated protein identified by researchers at the institute.
Subscribe to our email newsletter
Morphotek will apply its proprietary Human Morphodoma antibody technology to develop novel antibodies for use in the treatment of advanced melanoma, lung cancer and other solid malignancies that express the antigen. The JWCI will provide its expertise in characterizing and evaluating the specificity and efficacy of these antibodies in bench studies and clinical trials.
“Morphotek’s sophisticated hybridoma technology provides JWCI researchers another important tool to investigate the efficacy of therapeutic antibodies,” said Dr Donald Morton, medical director and Surgeon-in-Chief at the JWCI. “JWCI’s unique melanoma program and Morphotek’s innovative technology represent a potent combination that should rapidly yield effective immune-based treatment for melanoma and other cancers.”